Firsocostat is an acetyl-CoA carboxylase inhibitor that functions in the liver. Its original designation was GS-0976.[1] It was discovered by Nimbus Therapeutics.[2] The drug is under development by Gilead as a treatment for non-alcoholic fatty liver disease.[3]
Quick Facts Names, Identifiers ...
Firsocostat
 |
Names |
IUPAC name
2-[1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid |
Identifiers |
|
|
|
|
ChEMBL |
|
ChemSpider |
|
DrugBank |
|
|
|
KEGG |
|
|
|
UNII |
|
InChI=1S/C28H31N3O8S/c1-16-21-24(32)31(28(2,3)26(33)34)27(35)30(25(21)40-22(16)23-29-11-14-38-23)15-20(39-17-9-12-37-13-10-17)18-7-5-6-8-19(18)36-4/h5-8,11,14,17,20H,9-10,12-13,15H2,1-4H3,(H,33,34)/t20-/m0/s1 Key: ZZWWXIBKLBMSCS-FQEVSTJZSA-N
|
CC1=C(SC2=C1C(=O)N(C(=O)N2C[C@@H](C3=CC=CC=C3OC)OC4CCOCC4)C(C)(C)C(=O)O)C5=NC=CO5
|
Properties |
|
C28H31N3O8S |
Molar mass |
569.63 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Close